tradingkey.logo

Merck Enters Exclusive License Agreement For HRS-5346 From Jiangsu Hengrui Pharmaceuticals

ReutersMar 25, 2025 10:53 AM

- Merck & Co Inc MRK.N:

  • MERCK & CO- SEES TO RECORD PRE-TAX CHARGE OF $200 MILLION, OR ABOUT $0.06 PER SHARE, TO BE INCLUDED IN GAAP AND NON-GAAP RESULTS IN QUARTER DEAL CLOSES

  • MERCK ENTERS EXCLUSIVE LICENSE AGREEMENT FOR HRS-5346, AN INVESTIGATIONAL ORAL LIPOPROTEIN(A) INHIBITOR, FOR CARDIOVASCULAR DISEASE FROM JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

  • MERCK & CO INC - HENGRUI PHARMA TO RECEIVE $200 MILLION UPFRONT PAYMENT FROM MERCK

  • MERCK & CO INC - HENGRUI PHARMA ELIGIBLE FOR UP TO $1.77 BILLION IN MILESTONE PAYMENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI